600420 Shanghai Shyndec Pharmaceutical
- 11.40
- -0.13-1.13%
Shanghai Shyndec Pharmaceutical News
Sinopharm Hyundai (600420.SH): The holding company became the marketing license holder for desloratadine oral solution (100ml: 50mg)
Sinopharm Hyundai (600420.SH) announced that recently, Sinopharm Group Zhijun (Shenzhen) Pharmaceuticals, a holding subsidiary of the company, has...
Sinopharm Hyundai (600420.SH): Cooperation Framework Agreement Terminated at Expiration
Gelonghui, May 22丨Sinopharm Hyundai (600420.SH) announced that on June 10, 2021, it signed a “Cooperation Framework Agreement on Commissioning Exclusive Production and Exclusive Sales of Pharmaceutical Products and Provision of Marketing Services” with Xi'an Xintong Pharmaceutical Research Co., Ltd. (hereinafter referred to as Xi'an Xintong), agreeing that Xi'an Xintong is in the R&D process, has intellectual property rights, and entrusts three pharmaceutical products as drug marketing license holders to Sinopharm Hyundai for exclusive production and exclusive sale. In August 2022, due to policy influence, the two sides reached an agreement on CE-fosphenytoin injection, one of the cooperative products after negotiations
China Grants Registration Approval for Shanghai Shyndec Pharmaceutical Unit's Flu Injection
Shanghai Shyndec Pharmaceutical (SHA:600420) unit, Sinopharm Rongsheng Pharmaceutical received a drug registration certificate from China's National Medical Products Administration for its Peramivir i
Shanghai Shyndec Pharmaceutical Co., Ltd. (SHSE:600420) Held Back By Insufficient Growth Even After Shares Climb 33%
Shanghai Shyndec Pharmaceutical Co., Ltd. (SHSE:600420) shares have continued their recent momentum with a 33% gain in the last month alone. But the gains over the last month weren't enough to make
Shanghai Shyndec Pharmaceutical (SHSE:600420) Earnings and Shareholder Returns Have Been Trending Downwards for the Last Year, but the Stock Lifts 5.0% This Past Week
While not a mind-blowing move, it is good to see that the Shanghai Shyndec Pharmaceutical Co., Ltd. (SHSE:600420) share price has gained 26% in the last three months. But that doesn't change the fa
Sinopharm Hyundai (600420.SH) announced first-quarter results, net profit of 331 million yuan, up 84.83% year-on-year
According to Zhitong Finance App News, Sinopharm Hyundai (600420.SH) released its report for the first quarter of 2024. During the reporting period, the company achieved operating income of 3.123 billion yuan, a year-on-year decrease of 8.6%; net profit attributable to shareholders of listed companies was 331 million yuan, an increase of 84.83% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 326 million yuan, an increase of 91.04% year on year; basic earnings per share were 0.2470 yuan.
Sinopharm Hyundai (600420.SH): The company's current hypoglycemic drugs include engagliflozin tablets
Gelonghui, April 24 | Sinopharm Hyundai (600420.SH) said on the investor interactive platform that the company currently has glucose-lowering drugs such as engliflozin tablets, as well as the active ingredients acarbose and voglibose. None of the above drugs currently have any weight-loss-related indications.
Sinopharm Hyundai (600420.SH): Injectable ceftriaxone passes consistent evaluation of generic drug quality and efficacy
Sinopharm Hyundai (600420.SH) issued an announcement. Recently, Sinopharm Group Weiqida Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company...
Shyndec Pharmaceutical's Unit Gets Nod to Market Empagliflozin Tablets
Shanghai Shyndec Pharmaceutical's (SHA:600420) unit, Sinopharm Rongsheng Pharmaceutical, received a drug registration certificate from China's National Medical Products Administration for its empaglif
Sinopharm Hyundai (600420.SH): Empagliflozin tablets obtained drug registration certificate
Gelonghui, April 15 | Sinopharm Hyundai (600420.SH) announced that its wholly-owned subsidiary Sinopharm Group Rongsheng Pharmaceutical Co., Ltd. has received the “Drug Registration Certificate” for englizine tablets approved and issued by the State Drug Administration. Empagliflozin reduces the ability of the kidneys to recycle glucose back into the bloodstream and excretes sugar from the body through urine, which helps reduce patients' blood sugar levels.
Sinopharm Hyundai (600420.SH) sales are expected to increase. Net profit for the first quarter is expected to be 320 million yuan to 340 million yuan, an increase of 78.55% to 89.71% year-on-year
According to Zhitong Finance App News, Sinopharm Hyundai (600420.SH) released a performance forecast for the first quarter of 2024. It is expected to achieve net profit of 320 million yuan to 340 million yuan in the first quarter of 2024, an increase of 78.55% to 89.71% over the previous year. Net profit attributable to owners of the parent company after deducting non-recurring profit and loss was 311 million yuan to 337 million yuan, an increase of 82.30% to 97.54% over the previous year. The main reasons for the increase in performance during the reporting period are as follows: 1. In the first quarter, the company focused on market demand and adjusted the product structure of pharmaceutical intermediates and APIs, in part
Chinese FDA Grants Marketing Approval for Shyndec Subsidiary's Drug Raw Materials
China's food and drug administration granted marketing approval to Shanghai Shyndec Pharmaceutical (SHA:600420) subsidiary Sinopharm Yixin Pharmaceutical's trifluridine tipiracil preparation products,
We Think That There Are Some Issues For Shanghai Shyndec Pharmaceutical (SHSE:600420) Beyond Its Promising Earnings
Shanghai Shyndec Pharmaceutical Co., Ltd.'s (SHSE:600420) robust recent earnings didn't do much to move the stock. We believe that shareholders have noticed some concerning factors beyond the statuto
Sinopharm Hyundai (600420.SH) released 2023 results, net profit of 692 million yuan, up 10.21% year on year
Sinopharm Hyundai (600420.SH) released its 2023 annual report, achieving revenue of 12.07 billion yuan,...
China Production Bases of Shyndec Pharmaceutical's Unit Gets Compliance Certification From Australian Regulator
Shanghai Shyndec Pharmaceutical's (SHA:600420) unit, Sinopharm Zhijun (Shenzhen) Pharmaceutical, received certification from Australia's Therapeutic Goods Administration for its production bases after
Is Shanghai Shyndec Pharmaceutical (SHSE:600420) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Sinopharm Hyundai (600420.SH) subsidiary injectable remifentanil hydrochloride passed generic drug consistency evaluation
Sinopharm Hyundai (600420.SH) issued an announcement. Recently, Sinopharm Group Industrial Co., Ltd., a wholly-owned subsidiary of the company (...
Sinopharm Hyundai (600420.SH): Tranexamic acid injection passed generic drug consistency evaluation
Gelonghui March 12 丨 Sinopharm Hyundai (600420.SH) announced that the holding subsidiary Shanghai Hyundai Hasson (Shangqiu) Pharmaceutical Co., Ltd. received the “Drug Supplement Application Approval Notice” approved and issued by the State Drug Administration, approved tranexamic acid injections to increase product regulations and passed a consistent evaluation of the quality and efficacy of generic drugs. Blood medications up to tranexamic acid injections are mainly used for all kinds of bleeding caused by acute or slow, limited systemic hyperfibrinolysis.
Shyndec Pharma's Unit Gets Regulatory Nod for Sheep Vaccine
Shanghai Shyndec Pharmaceutical's (SHA:600420) unit, Qinghai Biopharmaceutical Factory, received approval from China's Ministry of Agriculture and Rural Affairs to produce and market its vaccine again
Shyndec Pharma Unit's Cefotaxime Sodium for Injection Passes Drug Regulator's Consistency Evaluation
Shanghai Shyndec Pharmaceutical (SHA:600420) subsidiary Sinopharm Weiqida Pharmaceutical's cefotaxime sodium for injection passed the quality and efficacy consistency evaluation of China's National Me
Analysis
Price Target
No Data
